Biohaven Completes Enrollment in Obesity Treatment Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 19 2026
0mins
Should l Buy BHVN?
Source: Newsfilter
- Enrollment Completion: Biohaven announced the completion of enrollment in its Phase 2 study of taldefgrobep alfa for obesity, with topline data expected in the second half of 2026, marking a significant advancement in the company's obesity treatment efforts.
- Efficacy Assessment: The study will evaluate the efficacy of once-weekly and once-monthly taldefgrobep monotherapy, targeting approximately 150 participants, with primary measures focusing on weight change, reflecting the company's ongoing commitment to obesity treatment.
- Favorable Safety Profile: Taldefgrobep has demonstrated a favorable safety and tolerability profile in over 700 trial participants, with low rates of adverse events, establishing a solid foundation for its application in chronic weight management.
- Market Potential: The novel mechanism of taldefgrobep may provide significant benefits in fat reduction and muscle gain, with Biohaven believing it could offer new treatment options for obesity patients, further driving growth in the biopharmaceutical sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BHVN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BHVN
Wall Street analysts forecast BHVN stock price to rise
13 Analyst Rating
9 Buy
4 Hold
0 Sell
Moderate Buy
Current: 8.610
Low
11.00
Averages
18.00
High
30.00
Current: 8.610
Low
11.00
Averages
18.00
High
30.00
About BHVN
Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biohaven Shares Enter Oversold Territory
- Oversold Signal: Biohaven Ltd (Ticker: BHVN) saw its RSI drop to 29.9 during Tuesday's trading, indicating an oversold condition as shares hit a low of $8.28, suggesting that recent heavy selling may be nearing exhaustion, prompting bullish investors to seek buying opportunities.
- Market Comparison: Compared to the current RSI of 38.6 for the S&P 500 ETF (SPY), BHVN's 29.9 RSI indicates relative weakness, potentially attracting investors looking for a rebound, especially amid increasing market volatility.
- Price Fluctuation: BHVN's 52-week low stands at $7.48 per share, with a high of $31.18, while the latest trade price is $8.39, indicating that the stock is hovering at low levels, which may present potential buying opportunities for investors.
- Investor Sentiment: Despite the current low stock price, investors should carefully assess market sentiment and fundamental factors to determine whether to invest under the oversold signal, avoiding potential risks.
See More
Sarissa Capital Management Acquires Stake in Biohaven Ltd.
- New Investment Position: Sarissa Capital Management established a new position in Biohaven Ltd. (BHVN) during Q4 2026 by acquiring 513,184 shares valued at approximately $5.79 million, indicating a strategic move into the biopharmaceutical sector.
- Increased Ownership Percentage: This acquisition brings Biohaven to 2.6% of Sarissa's reportable U.S. equity AUM, reflecting a strategic emphasis on the company despite its stock price plummeting 70% over the past year.
- Financial Condition Overview: Biohaven ended 2025 with around $322 million in cash and raised an additional $178.9 million post-year-end, maintaining a relatively stable financial position despite facing FDA rejections and disappointing trial results.
- Future Growth Potential: Biohaven is focusing on late-stage programs, including a Phase 2 obesity candidate, with data expected in the second half of 2026, which could provide new growth momentum if successful.
See More
Sarissa Capital Management Increases Stake in Biohaven
- New Investment Position: Sarissa Capital Management initiated a new position in Biohaven Ltd. by acquiring 513,184 shares in Q4 2025, resulting in a quarter-end valuation of $5.79 million, indicating a strategic expansion into the biotech sector.
- Strong Financial Position: Despite facing FDA rejections and disappointing trial updates, Biohaven ended 2025 with approximately $322 million in cash and raised an additional $178.9 million post-year-end, providing crucial time for key clinical readouts.
- Focus on Core Programs: Biohaven's management is concentrating resources on a smaller set of late-stage programs, including a degrader platform and an obesity candidate with data expected later in 2026, showcasing the company's strategic adaptability in a tight capital environment.
- Market Sentiment Challenges: Although Biohaven's stock has been impacted by FDA rejections and poor trial results, Sarissa's increased stake reflects confidence in the company's future potential, especially as upcoming clinical data and execution will be critical factors moving forward.
See More
DAFNA Capital Management Increases Biohaven Stake
- Increased Holdings: DAFNA Capital Management acquired 720,000 shares of Biohaven in Q4 2025, with an estimated trade value of $8.92 million, indicating confidence in the company's future potential.
- Value Appreciation: By quarter-end, DAFNA's total stake value reached $10.78 million, up $7.25 million from the previous period, reflecting both stock price movements and the addition of new shares.
- Strategic Focus: Biohaven is cutting spending and narrowing its focus to three late-stage programs; despite a net loss of approximately $739 million last year, the company is undergoing a strategic transformation aimed at enhancing market competitiveness.
- Improved Liquidity: With about $322 million in cash at year-end and additional capital raised thereafter, Biohaven's financial position appears more stable than its stock price suggests, providing potential opportunities for future growth.
See More
DAFNA Capital Increases Biohaven Stake by 720,000 Shares
- Share Increase: DAFNA Capital increased its stake in Biohaven by 720,000 shares during Q4 2025, with an estimated transaction value of $8.92 million, reflecting confidence in the company's future potential.
- Value Growth: Following this purchase, Biohaven's total stake value rose to $10.78 million, an increase of $7.25 million from the previous period, indicating the dual impact of stock price movements and additional shares.
- Portfolio Dynamics: Biohaven now represents 2.51% of DAFNA's reportable U.S. equity assets, highlighting its significance in the portfolio despite its overall poor performance.
- Company Transformation: Despite a net loss of approximately $739 million last year, Biohaven is focusing on three late-stage programs expected to yield important data this year, showcasing the company's potential and strategic adjustments during its transition.
See More
Biohaven Completes Enrollment in Obesity Treatment Clinical Trial
- Clinical Trial Enrollment Completed: Biohaven announced the completion of enrollment for its Phase 2 trial of taldefgrobep alfa, targeting approximately 150 participants, with topline data expected in the second half of 2026, potentially introducing a new treatment option for obesity.
- Efficacy Assessment Design: The trial employs a randomized, double-blind, placebo-controlled design to evaluate the monotherapy efficacy of taldefgrobep, primarily measuring weight change over 24 weeks, aiming to provide more effective treatment options for obese patients and potentially altering current treatment standards.
- Good Safety and Tolerability: Taldefgrobep has demonstrated good tolerability in over 700 clinical trial participants, with low rates of serious adverse events, indicating a promising outlook for its application in chronic weight management and positioning it as a next-generation obesity treatment.
- Innovative Mechanism and Market Potential: Taldefgrobep shows significant potential for improving body weight and fat mass by inhibiting activin receptor signaling, and its combination with GLP-1 agonists may open new market opportunities in obesity treatment, addressing the growing global demand for effective obesity therapies.
See More
Biohaven Shares Enter Oversold Territory
- Oversold Signal: Biohaven Ltd (Ticker: BHVN) saw its RSI drop to 29.9 during Tuesday's trading, indicating an oversold condition as shares hit a low of $8.28, suggesting that recent heavy selling may be nearing exhaustion, prompting bullish investors to seek buying opportunities.
- Market Comparison: Compared to the current RSI of 38.6 for the S&P 500 ETF (SPY), BHVN's 29.9 RSI indicates relative weakness, potentially attracting investors looking for a rebound, especially amid increasing market volatility.
- Price Fluctuation: BHVN's 52-week low stands at $7.48 per share, with a high of $31.18, while the latest trade price is $8.39, indicating that the stock is hovering at low levels, which may present potential buying opportunities for investors.
- Investor Sentiment: Despite the current low stock price, investors should carefully assess market sentiment and fundamental factors to determine whether to invest under the oversold signal, avoiding potential risks.
See More
Sarissa Capital Management Acquires Stake in Biohaven Ltd.
- New Investment Position: Sarissa Capital Management established a new position in Biohaven Ltd. (BHVN) during Q4 2026 by acquiring 513,184 shares valued at approximately $5.79 million, indicating a strategic move into the biopharmaceutical sector.
- Increased Ownership Percentage: This acquisition brings Biohaven to 2.6% of Sarissa's reportable U.S. equity AUM, reflecting a strategic emphasis on the company despite its stock price plummeting 70% over the past year.
- Financial Condition Overview: Biohaven ended 2025 with around $322 million in cash and raised an additional $178.9 million post-year-end, maintaining a relatively stable financial position despite facing FDA rejections and disappointing trial results.
- Future Growth Potential: Biohaven is focusing on late-stage programs, including a Phase 2 obesity candidate, with data expected in the second half of 2026, which could provide new growth momentum if successful.
See More
Sarissa Capital Management Increases Stake in Biohaven
- New Investment Position: Sarissa Capital Management initiated a new position in Biohaven Ltd. by acquiring 513,184 shares in Q4 2025, resulting in a quarter-end valuation of $5.79 million, indicating a strategic expansion into the biotech sector.
- Strong Financial Position: Despite facing FDA rejections and disappointing trial updates, Biohaven ended 2025 with approximately $322 million in cash and raised an additional $178.9 million post-year-end, providing crucial time for key clinical readouts.
- Focus on Core Programs: Biohaven's management is concentrating resources on a smaller set of late-stage programs, including a degrader platform and an obesity candidate with data expected later in 2026, showcasing the company's strategic adaptability in a tight capital environment.
- Market Sentiment Challenges: Although Biohaven's stock has been impacted by FDA rejections and poor trial results, Sarissa's increased stake reflects confidence in the company's future potential, especially as upcoming clinical data and execution will be critical factors moving forward.
See More
DAFNA Capital Management Increases Biohaven Stake
- Increased Holdings: DAFNA Capital Management acquired 720,000 shares of Biohaven in Q4 2025, with an estimated trade value of $8.92 million, indicating confidence in the company's future potential.
- Value Appreciation: By quarter-end, DAFNA's total stake value reached $10.78 million, up $7.25 million from the previous period, reflecting both stock price movements and the addition of new shares.
- Strategic Focus: Biohaven is cutting spending and narrowing its focus to three late-stage programs; despite a net loss of approximately $739 million last year, the company is undergoing a strategic transformation aimed at enhancing market competitiveness.
- Improved Liquidity: With about $322 million in cash at year-end and additional capital raised thereafter, Biohaven's financial position appears more stable than its stock price suggests, providing potential opportunities for future growth.
See More
DAFNA Capital Increases Biohaven Stake by 720,000 Shares
- Share Increase: DAFNA Capital increased its stake in Biohaven by 720,000 shares during Q4 2025, with an estimated transaction value of $8.92 million, reflecting confidence in the company's future potential.
- Value Growth: Following this purchase, Biohaven's total stake value rose to $10.78 million, an increase of $7.25 million from the previous period, indicating the dual impact of stock price movements and additional shares.
- Portfolio Dynamics: Biohaven now represents 2.51% of DAFNA's reportable U.S. equity assets, highlighting its significance in the portfolio despite its overall poor performance.
- Company Transformation: Despite a net loss of approximately $739 million last year, Biohaven is focusing on three late-stage programs expected to yield important data this year, showcasing the company's potential and strategic adjustments during its transition.
See More
Biohaven Completes Enrollment in Obesity Treatment Clinical Trial
- Clinical Trial Enrollment Completed: Biohaven announced the completion of enrollment for its Phase 2 trial of taldefgrobep alfa, targeting approximately 150 participants, with topline data expected in the second half of 2026, potentially introducing a new treatment option for obesity.
- Efficacy Assessment Design: The trial employs a randomized, double-blind, placebo-controlled design to evaluate the monotherapy efficacy of taldefgrobep, primarily measuring weight change over 24 weeks, aiming to provide more effective treatment options for obese patients and potentially altering current treatment standards.
- Good Safety and Tolerability: Taldefgrobep has demonstrated good tolerability in over 700 clinical trial participants, with low rates of serious adverse events, indicating a promising outlook for its application in chronic weight management and positioning it as a next-generation obesity treatment.
- Innovative Mechanism and Market Potential: Taldefgrobep shows significant potential for improving body weight and fat mass by inhibiting activin receptor signaling, and its combination with GLP-1 agonists may open new market opportunities in obesity treatment, addressing the growing global demand for effective obesity therapies.
See More
